CRSP

#1291
CRISPR Therapeutics AG
54.83 USD
+7.05%
Сектор: Здравоохранение
Базовая: USD
Валюта прибыли: USD
Дневной диапазон
54.83
54.83
Годовой диапазон
33.03
78.48
Дневное изменение
+7.05%
Месячное изменение
+10.77%
6-месячное изменение
-18.61%
Годовое изменение
+37.04%
Предыдущее закрытие
51.22
Открыть
54.83
Bid
Ask
Минимум
54.83
High
54.83
Объем
99
Открыть полный график

Financials

Обзор Отчетность Статистика
Квартал Год
  • Market Capitalization 5.26 B
  • Employee 393
  • Founded 2013
  • CEO Samarth Kulkarni
  • Website www.crisprtx.com
  • Headquarter Switzerland
  • FIGI UNKNOWN
  • Industry Technology
Общий доход
Чистая прибыль
Базовая прибыль на акцию
Общий долг
Свободный денежный поток
Денежные средства и эквиваленты
Коэффициент цена/прибыль
-8.11
Коэффициент цена/денежный поток
1 343.5

CRISPR Therapeutics AG

CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland, Boston, Massachusetts, San Francisco, California and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts won the Facilities of the Year Award award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, was granted regulatory approval by the US Food and Drug Administration in December 2023.

Новости